SCHEMBL277484

SCHEMBL277484

CNC(=O)CC(NC)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
PTGS2 P35354 1/20 0.35
THPO P40225 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MME P08473 1/20 0.35
LMNA P02545 2/20 0.34
MCL1 Q07820 1/20 0.34
FOLH1 Q04609 2/20 0.34
NAALAD2 Q9Y3Q0 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL27949540 0.83 CA2 (0.44) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL13340463 0.82 ATM (0.35) ATMMAPTKDM4ETHRBALOX15
SCHEMBL13258521 0.81 MMP2 (0.40) ATMLMNAMCL1MMP2MMP9
SCHEMBL17617892 0.81 MCL1 (0.34) ATMLMNAMCL1
SCHEMBL24252994 0.80 ALDH1A1 (0.37) ATMMAPTKDM4ETHRBALOX15
SCHEMBL20886556 0.80 MAPT (0.55) MAPTKDM4ETHRBALOX15NFKB1
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL18528187 0.80 CA2 (0.45) MAPTKDM4ETHRBALOX15NFKB1
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL167682 0.80 CA2 (0.45) MAPTKDM4ETHRBALOX15NFKB1
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL19741548 0.80 CA2 (0.45) MAPTKDM4ETHRBALOX15NFKB1
N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL2220 0.80 CA2 (0.45) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220208309-A1 PREDICTION OF SIDE-CHAIN DEGRADATION IN POLYMERS THROUGH PHYSICS BASED SIMULATIONS GENENTECH, INC. (US) 2022-06-30 US disclosed
US-20210205418-A1 TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY ASAHI KASEI PHARMA CORPORATION (JP) 2021-07-08 US disclosed
US-20200289621-A1 TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY ASAHI KASEI PHARMA CORPORATION (JP) 2020-09-17 US disclosed
EP-3564237-A1 UREA COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2019-11-06 EP disclosed
US-9999657-B2 Polymer-factor VIII moiety conjugates NEKTAR THERAPEUTICS (US) 2018-06-19 US disclosed
EP-2961432-B1 FORMULATIONS OF GROWTH HORMONE RELEASING FACTOR (GRF) MOLECULES WITH IMPROVED STABILITY THERATECHNOLOGIES INC (CA) 2018-04-25 EP disclosed
US-9861705-B2 Conjugates of an IL-2 moiety and a polymer NEKTAR THERAPEUTICS (US) 2018-01-09 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-20110165113-A1 POLYMER CONJUGATES OF V681-LIKE PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer NEKTAR THERAPEUTICS (US) 2011-06-09 US disclosed
US-20100160610-A1 Conjugates of an EPO Moiety and a Polymer NEKTAR THERAPEUTICS (US) 2010-06-24 US disclosed
US-20100130427-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-27 US disclosed
US-20100125049-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-20 US disclosed
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 US disclosed
US-7714114-B2 Conjugates of an EPO moiety and a polymer NEKTAR THERAPEUTICS (US) 2010-05-11 US disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
US-7199223-B2 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer BCHE, ACHE, DNPEP ATM 3891/4885MAPT 494/4885KDM4E 2231/4885
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B ATM 2304/4885MAPT 3026/4885KDM4E 2537/4885
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 ATM 2961/4885MAPT 2188/4885KDM4E 3324/4885
US-20100125049-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B ATM 2304/4885MAPT 3026/4885KDM4E 2537/4885
US-20210205418-A1 TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY PTH1R, THOP1, SOST ATM 4486/4885MAPT 2376/4885KDM4E 4161/4885
US-20200289621-A1 TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY PTH1R, THOP1, SOST ATM 4486/4885MAPT 2376/4885KDM4E 4161/4885
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP ATM 4633/4885MAPT 405/4885KDM4E 4758/4885
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer CSF3R, GMFG, CSF1R ATM 1933/4885MAPT 1191/4885KDM4E 4396/4885
US-20110165113-A1 POLYMER CONJUGATES OF V681-LIKE PEPTIDES NGLY1, VIP, DNPEP ATM 4796/4885MAPT 1166/4885KDM4E 4740/4885
US-20100160610-A1 Conjugates of an EPO Moiety and a Polymer EPOR, EPRS1, NPPA ATM 4522/4885MAPT 3167/4885KDM4E 4201/4885
US-20100130427-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B ATM 2415/4885MAPT 2860/4885KDM4E 2604/4885
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER IL15, IL15RA, IL2 ATM 3797/4885MAPT 1315/4885KDM4E 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.